Holen Sie sich die Stockscreener-App
1.55
6.03%
-0.11
Cognition Therapeutics Inc Aktie (CGTX) Neueste Nachrichten
Should you avoid Cognition Therapeutics Inc. stock right nowWeekly Investment Recap & Risk Adjusted Buy and Sell Alerts - newsyoung.net
Cognition Therapeutics Reports Q2 2025 Financial Results - TipRanks
CGTX Soars 33% on FDA Green Light and Trial Triumphs: Is This the Dawn of a Biotech Breakout? - AInvest
CGTX Plunges 10.66% Despite FDA Boost - AInvest
CGTX Stock Surge: Deciphering the Spike - StocksToTrade
Cognition Therapeutics stock jumps after FDA confirms Phase 3 design By Investing.com - Investing.com Nigeria
Is CGTX Stock About to Skyrocket? - timothysykes.com
CGTX Soars 34.55% on FDA Phase 3 Trial Endorsement - AInvest
Cognition Therapeutics Inc. (CGTX) Soars 25.45% on FDA Trial Endorsement - AInvest
Cognition Therapeutics shares rise 32.73% premarket after FDA confirms Phase 3 program design for Alzheimer's treatment. - AInvest
Cognition Therapeutics Stock Price, Quotes and Forecasts | NASDAQ:CGTX - Benzinga
Cognition Therapeutics Surges 30% Pre-Market After FDA Backs Phase 3 Trial Design For Alzheimer's Drug - Benzinga
Regulatory Clarity and Accelerated Path to Commercialization: Cognition Therapeutics' Strategic Position in Alzheimer's Therapeutics - AInvest
Cognition Therapeutics Receives End-of-Phase 2 Meeting - GlobeNewswire
Cognition Therapeutics shares rise 30% after-hours following FDA alignment on Phase 3 program for Alzheimer’s treatment. - AInvest
Cognition Therapeutics aligns with FDA on Alzheimer’s drug phase 3 design - Investing.com
Breakthrough Alzheimer's Drug Zervimesine Advances to Phase 3 with Novel Blood Test Strategy - Stock Titan
Cognition (CGTX) Surges 21.7% on Biotech Sector Volatility: What’s Fueling the Rally? - AInvest
Cognition Therapeutics Maintains Buy Rating Amid Regulatory Milestones and Promising Developments - AInvest
Alzheimer's disease Clinical Trials, Companies, Therapeutic - openPR.com
Alzheimer’s disease Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline | AriBio Co., Ltd., Eli Lilly & Co., Cognition Therapeutics, AbbVie Inc., Allyx Therape - Barchart.com
Cognition Therapeutics Reports Positive Q2 Earnings, Advances Clinical Programs for Neurodegenerative Disorders - AInvest
Cognition Therapeutics Reports Q2 2025 GAAP Grant Income of $7.1mln, Exceeding Analyst Expectations - AInvest
Cognition Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Cognition Therapeutics reports Q2 EPS (11c), consensus (10c) - TipRanks
Cognition Therapeutics Reports Q2 2025 Results, Highlights Clinical Progress - AInvest
Cognition Therapeutics: Pivotal Alzheimer's Milestones and Strategic Pathways to Value Creation in 2025 - AInvest
Cognition Therapeutics Reports Financial Results for the - GlobeNewswire
Breakthrough Alzheimer's Drug Shows 28% Success Rate as Cognition Advances Multiple Clinical Programs - Stock Titan
Published on: 2025-08-05 16:54:31 - beatles.ru
Top Risks to Consider Before Buying Cognition Therapeutics Inc. StockWeekly Chart Analysis With Entry Advice Provided - metal.it
Is Cognition Therapeutics Inc. a good long term investmentCapitalize on momentum-driven stocks - Jammu Links News
What are the latest earnings results for Cognition Therapeutics Inc.Invest confidently with real-time updates - Jammu Links News
What catalysts could drive Cognition Therapeutics Inc. stock higher in 2025Superior profit margins - Jammu Links News
What makes Cognition Therapeutics Inc. stock price move sharplyMaximize returns with disciplined trading approaches - Jammu Links News
Is it the right time to buy Cognition Therapeutics Inc. stockTriple-digit returns - Jammu Links News
Why is Cognition Therapeutics Inc. stock attracting strong analyst attentionFree Daily Trading Room Entry - Jammu Links News
How volatile is Cognition Therapeutics Inc. stock compared to the marketBreakthrough capital growth - Jammu Links News
What analysts say about Cognition Therapeutics Inc. stockDynamic growth stocks - Jammu Links News
What institutional investors are buying Cognition Therapeutics Inc. stockAchieve rapid returns with smart investment plans - jammulinksnews.com
Does Cognition Therapeutics Inc. stock perform well during market downturnsGet exclusive access to premium stock research - Jammu Links News
Cognition Therapeutics’ Expanded Access Program for CT1812: A Promising Update for Investors - The Globe and Mail
Is Cognition Therapeutics Inc. a growth stock or a value stockValue Investing Entry Points With Proven Results - Jammu Links News
What are analysts’ price targets for Cognition Therapeutics Inc. in the next 12 monthsPost Market Recommendation With High Returns - Jammu Links News
Cognition Therapeutics’ drug shows 129% cognitive decline arrest in mild Alzheimer’s - Yahoo Finance
Cognition Therapeutics shares fall 4.18% premarket after presenting mixed results from Phase 2 SHIMMER study. - AInvest
Published on: 2025-07-29 20:05:06 - metal.it
Applying sector rotation models to Cognition Therapeutics Inc.Long Hold Safe Return Strategy Reviewed - metal.it
New Data: Zervimesine for the Treatment of Dementia With Lewy Bodies and Alzheimer Disease - Psychiatric Times
How high can Cognition Therapeutics Inc. stock price go in 2025Conservative Long Term Growth Plans Under Review - metal.it
Cognition Therapeutics Presents Data at AAIC Highlighting - GlobeNewswire
Breakthrough Drug Zervimesine Halts Alzheimer's Decline by 129%, Shows Promise in Lewy Body Dementia - Stock Titan
Cognition Therapeutics shares rise 3.50% premarket after PTC Therapeutics' FDA approval of Sephience. - AInvest
0.07%
0.72%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):